Summarized by Masters of Longevity from PR Newswire.
Announcement that a genomics-led AI drug discovery partnership will expand into cardiovascular target discovery, leveraging large multiomic datasets and AI analytics.
Key Takeaways
- Variant Bio and Boehringer Ingelheim expanded their multi-year collaboration to include cardiovascular disease target discovery.
- Variant Bio's Inference platform will be applied to integrate genomic, deep-phenotyping, and multi-omic data for target identification.
- The expanded deal includes additional upfront and milestone payments with potential total value exceeding $250 million.
